Login
Super Investors Indaba Capital Management, L.P.
IC

Indaba Capital Management, L.P.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
—
Positions
1
Quarter ended
June 30, 2026
Filed
August 05, 2026

Reported portfolio value by quarter (51 quarters reported)

$944M —
Q4 13 Q3 16 Q2 19 Q1 22 Q4 24 Q2 26

$269M in Q4 2013 → — now. Hover for any quarter.

Holdings

As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
N None NaN% Unchanged 0 —

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q2 2026

quarter ended June 30, 2026 · filed August 05, 2026

No position changes this quarter.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
On24 Inc Exited −4,240,256 −$33.8M —
N None New +0 — —

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Ironwood Pharmaceuticals Inc Exited −20,000,000 −$17.8M —
Bandwidth Inc Exited −13,000,000 −$11.1M —
SH Summit Hotel Pptys Exited −6,539,000 −$6.44M —
Elme Communities Exited −66,502 −$1.12M —

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Bandwidth Inc Trimmed −27,250,000 −$23.2M 18.3%
SH Summit Hotel Pptys Trimmed −22,500,000 −$22.2M 10.6%
Travere Therapeutics Inc Exited −13,000,000 −$12.8M —
Blackbaud Inc Exited −193,000 −$12.4M —
AB Atlanta Braves Hldgs Inc Exited −93,811 −$4.39M —
ET Esperion Therapeutics Inc Ne Exited −3,000,000 −$2.95M —
Ironwood Pharmaceuticals Inc Added +3,000,000 +$2.67M 29.3%
Embecta Corp Exited −221,938 −$2.15M —
Advantage Solutions Inc Exited −980,865 −$1.29M —
Elme Communities New +66,502 +$1.12M 1.8%

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Accelerate Diagnostics Inc Exited −37,049,299 −$18.5M —
EC Equity Comwlth Exited −8,403,411 −$13.5M —

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
BO Blue Owl Cap Corp Iii Exited −2,793,366 −$40.3M —
RT Revance Therapeutics Inc Exited −25,000,000 −$24M —
Blackbaud Inc New +193,000 +$12M 7.2%
Accelerate Diagnostics Inc Added +12,363,301 +$6.18M 11.1%
SH Summit Hotel Pptys Added +6,375,000 +$6.1M 16.7%
AB Atlanta Braves Hldgs Inc New +93,811 +$3.75M 2.3%
Embecta Corp New +221,938 +$2.83M 1.7%
Ironwood Pharmaceuticals Inc Added +3,000,000 +$2.66M 9.1%
EC Equity Comwlth Trimmed −1,146,589 −$1.85M 8.1%
Advantage Solutions Inc New +980,865 +$1.48M 0.9%

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
BO Blue Owl Cap Corp Iii New +2,793,366 +$40.3M 19.4%
ET Esperion Therapeutics Inc Ne Exited −33,750,000 −$32M —
RT Revance Therapeutics Inc New +25,000,000 +$24M 11.6%
Xometry Inc Exited −21,750,000 −$18.6M —
SH Summit Hotel Pptys Added +18,164,000 +$17.6M 10.6%
Travere Therapeutics Inc New +13,000,000 +$12.8M 6.2%
EC Equity Comwlth Added +4,850,000 +$8.58M 8.1%
Standard Biotools Inc Exited −7,660,000 −$7.63M —
ET Esperion Therapeutics Inc Ne New +3,000,000 +$6.6M 3.2%
Ironwood Pharmaceuticals Inc Added +5,000,000 +$4.66M 6.3%

Showing the 10 largest of 11 changes.

Q3 2024

quarter ended September 30, 2024 · filed November 14, 2024

Company Action Shares changed Value of change % of portfolio
EC Equity Comwlth Added +2,000,000 +$39.8M 40.0%
ET Esperion Therapeutics Inc Ne Added +32,750,000 +$31.1M 13.7%
Blackline Inc Exited −292,000 −$14.1M —
Ironwood Pharmaceuticals Inc New +9,000,000 +$7.96M 3.4%
Standard Biotools Inc New +7,660,000 +$7.63M 3.3%
Bandwidth Inc Trimmed −9,000,000 −$7.02M 13.4%
SH Summit Hotel Pptys New +4,500,000 +$4.25M 1.8%
Xometry Inc Added +4,000,000 +$3.41M 7.9%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support